It has been suggested that HIV infection has a detrimental impact on patients with hepatocellular carcinoma (HCC). The present study sought to test this hypothesis, while controlling for tumor extension and liver disease.Design and Setting:
A case control and a cohort approach were performed in patients with HCC managed prospectively via dedicated multidisciplinary team meeting in a single tertiary institution between 2004 and 2009.Subjects:
Of 473 consecutive treatment-naive patients with HCC, 23 were HIV-positive (HIV+) and 450 were HIV-negative (HIV−). HIV+ patients were matched 1:2 with a control group of HIV− patients in terms of the etiology of HCC, the severity of liver disease, tumor extension, and year of diagnosis.Intervention:
Curative or palliative treatment of HCC.Main Outcome Measures:
Eligibility for HCC treatment, the treatment actually administered, and the survival rate.Results:
The HIV+ population was younger than the HIV− population (mean age: 49 vs. 61 years, respectively; P < 0.0001). Curative treatment was recommended by the multidisciplinary team meeting and then actually performed to a similar extent in HIV+ patients (74% and 43%, respectively) and their matched HIV− controls (74% and 56%, respectively). The HIV+ and their matched HIV− patients did not differ significantly in terms of the 3-year survival rate [44% vs. 48%, respectively; mean (95% confidence interval) hazard ratio = 0.64 (0.3–1.3); P = 0.2]. In a cohort analysis, HIV status was not an independent predictor of survival among curatively treated patients.Conclusion:
In an equal-access unbiased environment, HIV status does not significantly influence treatment access, delivery, and outcome.